Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancer-Reference-Cited by-同舟云学术

Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancer

Published:2023-09-01 Issue:17 Volume:133 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Konen Jessica M.^ORCID,Rodriguez B. Leticia,Wu Haoyi,Fradette Jared J.^ORCID,Gibson Laura^ORCID,Diao Lixia,Wang Jing,Schmidt Stephanie,Wistuba Ignacio I.,Zhang Jianjun^ORCID,Gibbons Don L.^ORCID

Funder

National Cancer Institute

CPRIT

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/163128/files/pdf

Reference62 articles.

1. Surveillance, Epidemiology, and End Results Program. Stat Fact Sheets: Lung and Bronchus. http://seer.cancer.gov/statfacts/html/lungb.html Accessed June 14, 2022

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

5. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10;Acta Pharmacologica Sinica;2024-08-26

2. Targeting metabolic pathways to counter cancer immunotherapy resistance;Trends in Immunology;2024-07

3. Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells;The Journal of Gene Medicine;2024-06

4. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities;Trends in Pharmacological Sciences;2024-06

5. The Emerging Role of LPA as an Oncometabolite;Cells;2024-04-04